ASCUS-LSIL Triage Study

OBJECTIVE To describe the design and methods of the ASCUS-LSIL Triage Study (ALTS), a multicenter, randomized clinical trial designed to evaluate three alternative methods of managing low grade (LSIL) and equivocal (ASCUS) cervical cytologic diagnoses. STUDY DESIGN Nonpregnant women, 18+ years old, with ASCUS or LSIL, no prior hysterectomy or ablative therapy to the cervix, were referred to one of four clinical centers around the United States. Eligible and consenting participants were administered a risk-factor questionnaire and underwent a pelvic examination, collection of cervical specimens for liquid-based cytology and human papillomavirus (HPV) testing and Cervicography (National Testing Laboratories, Fenton, Missouri, U.S.A.). Patients were randomized to one of three arms: (1) immediate referral for colposcopy at enrollment, (2) follow-up with cytology only, and (3) use of HPV DNA testing to triage to colposcopy. All women are followed every six months for two years with pelvic examinations, cytologic and masked HPV testing, and masked Cervicography. Digital cervical images and cytology and histology slides are externally reviewed to maximize patient safety. RESULTS We enrolled and randomized 3,488 eligible women with ASCUS and 1,572 women with LSIL. CONCLUSION The successful enrollment, randomization and high rates of follow-up are encouraging. The study will help clarify the optimal strategies for managing low grade cervical abnormalities.

[1]  M. Schiffman,et al.  Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.

[2]  J. Cuzick,et al.  Psychosexual trauma of an abnormal cervical smear , 1988, British journal of obstetrics and gynaecology.

[3]  R Reid,et al.  Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. , 1992, Obstetrics and gynecology.

[4]  J. Cuzick,et al.  PROGRESSIVE POTENTIAL OF MILD CERVICAL ATYPIA: PROSPECTIVE CYTOLOGICAL, COLPOSCOPIC, AND VIROLOGICAL STUDY , 1986, The Lancet.

[5]  F. Wiklund,et al.  Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. , 1999, The New England journal of medicine.

[6]  C. Brown,et al.  The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. , 1990, Acta cytologica.

[7]  L. Koss The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. , 1989, JAMA.

[8]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.

[9]  Diane Solomon,et al.  The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses , 1994, Springer US.

[10]  C. Peyton,et al.  Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method , 1998, Journal of Clinical Microbiology.

[11]  R. Burk,et al.  Natural history of cervicovaginal papillomavirus infection in young women , 1998 .

[12]  T. Wright,et al.  Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. , 1998, American journal of obstetrics and gynecology.

[13]  A. Forsythe,et al.  A Comparison of the Papanicolaou Smear and the Cervigram: Sensitivity, Specificity, and Cost Analysis , 1988, Obstetrics and gynecology.

[14]  C. Peyton,et al.  Comparison of PCR- and Hybrid Capture-Based Human Papillomavirus Detection Systems Using Multiple Cervical Specimen Collection Strategies , 1998, Journal of Clinical Microbiology.

[15]  W. Prendiville,et al.  Large loop excision of the transformation zone , 1991, The Lancet.

[16]  S Wacholder,et al.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. , 2000, JAMA.

[17]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[18]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[19]  A. Štafl,et al.  Cervicography: a new method for cervical cancer detection. , 1981, American journal of obstetrics and gynecology.

[20]  M. Schiffman,et al.  Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. , 1992, Journal of the National Cancer Institute.

[21]  L. Mango,et al.  Cervicography Screening for Cervical Cancer Among 8,460 Women in a High-Risk Population , 1999 .

[22]  George S. Ansell,et al.  Co-Principal Investigators: , 1984 .

[23]  J. Cuzick,et al.  Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer , 1992, The Lancet.

[24]  David R. Scott,et al.  Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. , 1999, Journal of the National Cancer Institute.

[25]  M. Schiffman,et al.  Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. , 1994, JAMA.

[26]  David R. Scott,et al.  Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.

[27]  Brown Cl,et al.  The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. , 1990, Acta cytologica.

[28]  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. , 1995, American journal of obstetrics and gynecology.

[29]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International Journal of Gynecological Pathology.

[30]  Steven Wolinsky,et al.  The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses , 1989 .

[31]  D. H. Wahl,et al.  Principal Investigator , 2020, Encyclopedic Dictionary of Archaeology.

[32]  L. Mango,et al.  Cervicography screening for cervical cancer among 8460 women in a high-risk population. , 1999, American journal of obstetrics and gynecology.

[33]  K. Holmes,et al.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection , 1992, The New England journal of medicine.

[34]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[35]  L. Mango,et al.  Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing , 1997, Cancer.

[36]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[37]  P. Fuchs,et al.  Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of the cervix uteri , 1988, International journal of cancer.

[38]  C. Meijer,et al.  Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study , 1999, The Lancet.

[39]  David R. Scott,et al.  Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. , 1994, American journal of clinical pathology.

[40]  W. Creasman,et al.  Evaluation of the atypical Pap smear. , 1987, American journal of obstetrics and gynecology.

[41]  Jorma Paavonen,et al.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. , 1992 .

[42]  M. Sherman,et al.  Reclassification of negative smears as atypical squamous cells of undetermined significance in quality assurance reviews , 1999, Cancer.

[43]  R. Burk,et al.  PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems , 1997, Journal of clinical microbiology.

[44]  R. Hiatt,et al.  Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. , 1999, JAMA.